2. Search Result
Search Result
Results for "

norepinephrine release

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

4

Peptides

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-137683A
    Guanosine 5'-O-2-thiodiphosphate trisodium

    GDPβS trisodium

    		 Adenylate Cyclase Cardiovascular Disease
    Guanosine 5'-O-(2-thiodiphosphate) trisodium (GDPβS trisodium) is a non-hydrolyzable derivative of GDP. Guanosine 5'-O-(2-thiodiphosphate) trisodium acts as an inhibitor of adenylyl cyclase (AC) with a Ki value of 600 nM. In the absence of glutamic-pyruvic transaminase (GPT) in cerebral cortex membranes of rodent models, Guanosine 5'-O-(2-thiodiphosphate) trisodium partially activates AC with an EC50 of 400 nM. Guanosine 5'-O-(2-thiodiphosphate) trisodium prevents norepinephrine-induced nitric oxide release in ventricular myocytes .
    Guanosine 5'-O-2-thiodiphosphate trisodium
  • HY-105856
    Thozalinone

    		Dopamine Receptor Neurological Disease
    Thozalinone is an orally active antidepressant agent. Thozalinone induces the release of Norepinephrine (HY-13715) and dopamine .
    Thozalinone
  • HY-12716A
    BRL-44408 maleate

    		Adrenergic Receptor ERK p38 MAPK Dopamine Receptor Cardiovascular Disease Neurological Disease
    BRL-44408 maleate is a selective, blood-brain barrier-permeable α2A-adrenergic receptor antagonist with a Ki value of 8.56 nM against human targets. BRL-44408 maleate exhibits activities such as antidepressant, analgesic effects and attenuation of sepsis-induced acute lung injury by regulating the release of neurotransmitters such as norepinephrine and dopamine, or inhibiting signaling pathways including ERK1/2, p38MAPK and p65. BRL-44408 maleate can be used in studies related to acute respiratory distress syndrome, depression and visceral pain .
    BRL-44408 maleate
  • HY-106865
    Mivazerol

    		Dopamine Receptor Adrenergic Receptor Cardiovascular Disease
    Mivazerol is a selective α2-adrenoceptor agonist. Mivazerol decreases the spontaneous release of serotonin (5-HT) and significantly inhibits the immobilization stress-induced enhancement of norepinephrine (NE), dopamine (DA) and dihydroxyphenylacetic acid (DOPAC). Mivazerol inhibits intrathecal release of glutamate evoked by halothane withdrawal in rats, and exerts neuroprotective effects in forebrain ischemia rats. Mivazerol can be used for myocardial ischemia research .
    Mivazerol
  • HY-B1202
    Alrestatin
    1 Publications Verification

    AY-22284

    		 Aldose Reductase Metabolic Disease
    Alrestatin (AY-22284) is an aldose reductase inhibitor. Alrestatin reduces fructose levels in the uterine fluid of mice. Alrestatin interferes with sperm capacitation and impairs fertilization function in mice. Alrestatin decreases basal and tyramine-induced norepinephrine release in rat pancreatic specimens in vitro. Alrestatin enhances glucose- and arginine-stimulated insulin secretion in vivo. Alrestatin can be used in studies related to diabetes and reproductive diseases .
    Alrestatin
  • HY-W685943
    Heptaminol

    		Adrenergic Receptor Cardiovascular Disease Neurological Disease
    Heptaminol is a fatty amine with pressor properties and a potential antihypotension agent. Heptaminol is also a competitive inhibitor of norepinephrine uptake and an inhibitor of nicotine-induced catecholamine release (IC50: 650 μM). Heptaminol does not inhibit norepinephrine release induced by 59 mM K + but rather inhibits high-affinity Na +-dependent norepinephrine uptake .
    Heptaminol
  • HY-18332C
    DOV-216,303 Free Base

    		Serotonin Transporter Dopamine Transporter Neurological Disease
    DOV-216,303 (Free Base) is a potent triple serotonin, norepinephrine, and dopamine reuptake inhibitor, with IC50 values of 14 nM, 20 nM and 78 nM for hSERT, hNET and hDAT, respectively. Has antidepressant-like effects and increases monoamine release in the prefrontal cortex of olfactory bulbectomized (OBX) rats .
    DOV-216,303 Free Base
  • HY-16094
    Bethanidine sulfate

    BW 467C60

    		 Adrenergic Receptor Cardiovascular Disease Neurological Disease
    Bethanidine sulfate is an orally active antihypertensive agent and adrenergic neuron blocker. Bethanidine sulfate exerts its antihypertensive effect by inhibiting the release of norepinephrine from sympathetic nerve terminals. Bethanidine sulfate exhibits anti-ventricular arrhythmic activity. Bethanidine sulfate can be used in research related to hypertension, ventricular tachycardia, and ventricular fibrillation .
    Bethanidine sulfate
  • HY-118387
    AVE-0118

    		Potassium Channel Cardiovascular Disease
    AVE-0118 is a Kv1.5 potassium channel blocker and antiarrhythmic agent. AVE-0118 blocks neuronal Kv1.5 potassium channels, thereby enhancing the release of norepinephrine. AVE-0118 enhances field stimulation-induced neurogenic contraction, an effect sensitive to α1-adrenergic receptor blockade. AVE-0118 terminates persistent atrial fibrillation in some dogs. AVE-0118 is applicable to research related to atrial fibrillation and persistent atrial fibrillation .
    AVE-0118
  • HY-12716
    BRL-44408

    		Adrenergic Receptor p38 MAPK Dopamine Receptor ERK Cardiovascular Disease Neurological Disease
    BRL-44408 is a selective, blood-brain barrier-permeable α2A-adrenergic receptor antagonist with a Ki value of 8.56 nM against human targets. BRL-44408 exhibits activities such as antidepressant, analgesic effects and attenuation of sepsis-induced acute lung injury by regulating the release of neurotransmitters such as norepinephrine and dopamine, or inhibiting signaling pathways including ERK1/2, p38MAPK and p65. BRL-44408 can be used in studies related to acute respiratory distress syndrome, depression and visceral pain .
    BRL-44408
  • HY-158552
    4-EEC hydrochloride

    		Dopamine Receptor Neurological Disease
    4-EEC hydrochloride is a synthetic stimulant substance. 4-EEC hydrochloride is a releasing agent for norepinephrine-dopamine .
    4-EEC hydrochloride
  • HY-W722796
    Tuaminoheptane sulfate

    		Adrenergic Receptor Others
    Tuaminoheptane sulfate is an alpha-adrenergic receptor agonist. Tuaminoheptane sulfate exerts its decongestant and irritant effects by inhibiting norepinephrine reuptake and promoting its release. Tuaminoheptane sulfate can be used in research on nasal diseases such as decongestion .
    Tuaminoheptane sulfate
  • HY-P11313
    Catestatin (rat)

    Rat chromogranin A367–387

    		 nAChR Akt Cardiovascular Disease
    Catestatin (rat) (Rat chromogranin A367–387) is a potent, reversible, noncompetitive, and noncooperative nicotinic cholinergic antagonist derived from chromogranin A (A367-387). Catestatin (rat) inhibits norepinephrine release in rat PC12 pheochromocytoma cells (IC50 = 1.2 μM), and blocks desensitization of norepinephrine release (IC50 = 0.62 μM). Catestatin (rat) exerts antiadrenergic effects through the endothelial PI3K-AKT-eNOS pathway in rat papillary muscles and isolated cardiomyocytes. Catestatin (rat) maintains mitochondrial membrane potential in I/R cardiomyocytes and increases phosphorylation of AKT at S473, GSK3β at S9, PLB at T17, and eNOS at S1179. Catestatin (rat) reverses desensitization of 22Na + uptake. Catestatin (rat) can be used for the study of nicotinic cholinergic receptor regulation and catecholamine release control mechanisms .
    Catestatin (rat)
  • HY-106504
    Aganodine

    		Imidazoline Receptor Neurological Disease
    Aganodine is a guanidine that activates presynaptic imidazoline receptors and can inhibit electrically evoked [ 3H]-norepinephrine release .
    Aganodine
  • HY-115762
    4-Hydroxytryptamine creatinine sulfate

    		Endogenous Metabolite Neurological Disease
    4-Hydroxytryptamine creatinine sulfate, a tryptamine derivative, is a neurotransmitter agonist .
    4-Hydroxytryptamine creatinine sulfate
  • HY-W922811
    DL-Willardiine

    		iGluR Neurological Disease
    DL-Willardiine is an AMPA antagonist with an IC50 of 2 μM. DL-Willardiine can be utilized in psychotropic cccccc research .
    DL-Willardiine
  • HY-14607
    Besipirdine hydrochloride

    HP 749

    		 Potassium Channel Neurological Disease
    Besipirdine (hydrochloride) is a potassium channel blocker with cholinergic and adrenergic activity. The cholinergic activity of Besipirdine (hydrochloride) involves stimulating phosphatidylinositol turnover and reducing potassium currents. The adrenergic activity of Besipirdine (hydrochloride) involves stimulating norepinephrine release, which is attributed to the inhibition of presynaptic α2-adrenergic receptors and the inhibition of norepinephrine uptake. Besipirdine (hydrochloride) may be used in research for Alzheimer's disease .
    Besipirdine hydrochloride
  • HY-W342779
    4-Bromoamphetamine hydrochloride

    		Dopamine Receptor Neurological Disease
    4-Bromoamphetamine hydrochloride is an amphetamine derivative which acts as a serotonin-norepinephrine-dopamine releasing agent (SNDRA) and produces stimulant effects. 4-Bromoamphetamine hydrochloride is highly neurotoxic, producing long-term depletion of serotonin .
    4-Bromoamphetamine hydrochloride
  • HY-129668
    Bremazocine

    		Adrenergic Receptor Neurological Disease
    Bremazocine is a potent opioid kappa receptor agonist with analgesic activity. Bremazocine induces peripheral analgesia by releasing endogenous norepinephrine. The analgesic effect of bremazocine is associated with interaction with adenosine receptors. Bremazocine produces a dose-dependent peripheral analgesia after topical application. The effect of bremazocine is affected by nonselective α(2) adrenaline receptor antagonists, suggesting that it acts through a norepinephrine pathway .
    Bremazocine
  • HY-P3064
    Scyllatoxin

    Leiurotoxin I

    		 Potassium Channel Neurological Disease
    Scyllatoxin (Leiurotoxin I) is a peptide toxin, it can be isolated from the venom of the scorpion (Leiurus quinquestriatus hebraeus). Scyllatoxin is a blocker of small-conductance KCa (SK) channel. Scyllatoxin enhances both norepinephrine (NE) and epinephrine (Epi) release in vivo .
    Scyllatoxin
  • HY-W061043
    DOV-216,303

    		Serotonin Transporter Dopamine Transporter Neurological Disease
    DOV-216,303 is an antidepressant compound. DOV-216,303 inhibits the reuptake of norepinephrine (NE), serotonin (5‐HT), and dopamine (DA), with IC50 values of 14 nM, 20 nM and 78 nM for hSERT, hNET and hDAT, respectively. DOV-216,303 increases monoamine release in the prefrontal cortex of olfactory bulbectomized (OBX) rats .
    DOV-216,303
  • HY-133858
    25N-NBOMe hydrochloride

    		5-HT Receptor Neurological Disease
    25N-NBOMe hydrochloride, a 2C-N derivative, is a 5-HT2A and 5-HT2C receptors agonist with Ki values of 0.144 nM and 1.06 nM, respectively. 25N-NBOMe hydrochloride has little to no efficacy at inducing release of preloaded neurotransmitter from recombinant dopamine, serotonin and norepinephrine transporters .
    25N-NBOMe hydrochloride
  • HY-111066
    JNJ-37822681

    		Dopamine Receptor Others
    JNJ-37822681 is a fast dissociating D2 antagonist with activity in inhibiting schizophrenia. JNJ-37822681 has high specificity for D2 receptors and is effective in animal models, inducing increased levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex, and exhibiting antidepressant activity in the mouse tail suspension test, while having a good brain distribution and lower prolactin release.
    JNJ-37822681
  • HY-B1202A
    Alrestatin sodium

    AY-22284A

    		 Aldose Reductase Metabolic Disease
    Alrestatin (AY-22284) sodium is an aldose reductase inhibitor. Alrestatin sodium reduces fructose levels in the uterine fluid of mice. Alrestatin sodium interferes with sperm capacitation and impairs fertilization function in mice. Alrestatin sodium decreases basal and tyramine-induced norepinephrine release in rat pancreatic specimens in vitro. Alrestatin sodium enhances glucose- and arginine-stimulated insulin secretion in vivo. Alrestatin sodium can be used in studies related to diabetes and reproductive diseases .
    Alrestatin sodium
  • HY-P1544
    Cerebellin

    		Endogenous Metabolite Adenylate Cyclase PKA Calcium Channel Neurological Disease Metabolic Disease
    Cerebellin is a neuromodulatory hexadecapeptide that serves as a marker for Purkinje cell maturation. Cerebellin stimulates norepinephrine release via the adenylate cyclase/PKA-dependent signaling pathway. Cerebellin reduces insulin secretion from pancreatic islets under high-glucose conditions. Cerebellin also regulates synaptic structure formation and controls catecholamine secretion in peripheral tissues. Cerebellin can be used in neurological research .
    Cerebellin
  • HY-B1202R
    Alrestatin (Standard)

    AY-22284 (Standard)

    		 Reference Standards Aldose Reductase Metabolic Disease
    Alrestatin (AY-22284) Standard is the analytical standard of Alrestatin (HY-B1202). This product is intended for research and analytical applications. Alrestatin (AY-22284) is an aldose reductase inhibitor. Alrestatin reduces fructose levels in the uterine fluid of mice. Alrestatin interferes with sperm capacitation and impairs fertilization function in mice. Alrestatin decreases basal and tyramine-induced norepinephrine release in rat pancreatic specimens in vitro. Alrestatin enhances glucose- and arginine-stimulated insulin secretion in vivo. Alrestatin can be used in studies related to diabetes and reproductive diseases.
    Alrestatin (Standard)
  • HY-172763
    EDMA hydrochloride

    		Drug Derivative Serotonin Transporter Dopamine Transporter 5-HT Receptor Neurological Disease
    EDMA hydrochloride is a derivative of MDMA. EDMA hydrochloride is a substrate for multiple neurotransmitter transporters, including serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET). EDMA hydrochloride has 5-HT releasing activity at SERT (EC50 = 117 nM) and MPP + releasing activity at DAT (EC50 = 597 nM) and NET (EC50 = 325 nM) .
    EDMA hydrochloride
  • HY-105856R
    Thozalinone (Standard)

    		Reference Standards Dopamine Receptor Neurological Disease
    Thozalinone (Standard) is the analytical standard of Thozalinone (HY-105856). This product is intended for research and analytical applications. Thozalinone is an orally active antidepressant agent. Thozalinone induces the release of Norepinephrine (HY-13715) and dopamine .
    Thozalinone (Standard)
  • HY-P1544A
    Cerebellin TFA

    		Calcium Channel PKA Endogenous Metabolite Adenylate Cyclase Neurological Disease Metabolic Disease
    Cerebellin TFA is a neuromodulatory hexadecapeptide that serves as a marker for Purkinje cell maturation. Cerebellin TFA stimulates norepinephrine release via the adenylate cyclase/PKA-dependent signaling pathway. Cerebellin TFA reduces insulin secretion from pancreatic islets under high-glucose conditions. Cerebellin TFA also regulates synaptic structure formation and controls catecholamine secretion in peripheral tissues. Cerebellin TFA can be used in neurological research .
    Cerebellin TFA
  • HY-W680886
    6-APDB

    		Monoamine Transporter Serotonin Transporter Dopamine Transporter 5-HT Receptor Neurological Disease
    6-APDB is a class of monoamine neurotransmitter releaser and Monoamine Transporter modulator that exerts selective effects on human monoamine transporters and acts as a partial agonist at 5-HT2 family receptors. For NET, 6-APDB has an IC50 of 0.56 μM and a Ki of 18 μM; for SERT, it has an IC50 of 2.3 μM and a Ki of 23 μM; for DAT, it has an IC50 of 33 μM and a Ki of >30 μM, and affinity for rat and mouse TAAR1, with Ki values of 1.0 μM and 0.21 μM, respectively. 6-APDB inhibits norepinephrine and 5-HT reuptake, mediates the release of three types of monoamine neurotransmitters, shows a dose-dependent biphasic locomotor effect in mice, and fully substitutes the discriminative stimulus effect of MDMA. 6-APDB shows no significant cytotoxicity at high concentrations, and possesses empathogenic psychoactivity, potential hallucinogenic effects, and behavioral effects associated with intermittent abuse .
    6-APDB

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: